No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

BACKGROUND: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Liver Cancer
Asıl Yazarlar: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Kawano, Reo, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: S. Karger AG 2018
Konular:
Original Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249591/
https://ncbi.nlm.nih.gov/pubmed/30488024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487858
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller